X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (95) 95
Publication (14) 14
Patent (11) 11
Newspaper Article (6) 6
Dissertation (4) 4
Book / eBook (1) 1
Book Chapter (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (30) 30
index medicus (30) 30
oncology (28) 28
female (18) 18
male (17) 17
cancer (16) 16
carcinoma, renal cell - drug therapy (16) 16
sunitinib (15) 15
animals (14) 14
article (14) 14
kidney neoplasms - drug therapy (14) 14
middle aged (14) 14
renal cell carcinoma (14) 14
aged (13) 13
peptides (12) 12
chemistry (11) 11
human necessities (11) 11
hygiene (11) 11
medical or veterinary science (11) 11
metallurgy (11) 11
microbiology (11) 11
organic chemistry (11) 11
preparations for medical, dental, or toilet purposes (11) 11
therapy (11) 11
angiogenesis (10) 10
beer (10) 10
biochemistry (10) 10
carcinoma, renal cell - pathology (10) 10
enzymes (10) 10
enzymology (10) 10
mice (10) 10
mutation or genetic engineering (10) 10
spirits (10) 10
vinegar (10) 10
wine (10) 10
expression (9) 9
kidney neoplasms - pathology (9) 9
adult (8) 8
cell line, tumor (8) 8
interferon-alpha (8) 8
neoplasm metastasis (8) 8
antiangiogenic therapy (7) 7
growth (7) 7
metastasis (7) 7
treatment outcome (7) 7
vascular endothelial growth factor a - antagonists & inhibitors (7) 7
abridged index medicus (6) 6
angiogenesis inhibitors - pharmacology (6) 6
angiogenesis inhibitors - therapeutic use (6) 6
bevacizumab (6) 6
risk factors (6) 6
vascular endothelial growth factor (6) 6
antineoplastic agents - therapeutic use (5) 5
care and treatment (5) 5
clear cell-type renal cell carcinoma (5) 5
combination (5) 5
everolimus (5) 5
immunotherapy (5) 5
inhibition (5) 5
mice, nude (5) 5
renal cancer (5) 5
research (5) 5
survival (5) 5
aged, 80 and over (4) 4
angiogenesis inhibitors - administration & dosage (4) 4
antineoplastic combined chemotherapy protocols - administration & dosage (4) 4
antineoplastic combined chemotherapy protocols - therapeutic use (4) 4
biomarker (4) 4
biomarkers (4) 4
cell biology (4) 4
cell proliferation - drug effects (4) 4
chemotherapy (4) 4
disease-free survival (4) 4
dose-response relationship, drug (4) 4
genetic aspects (4) 4
health aspects (4) 4
immunology (4) 4
kaplan-meier estimate (4) 4
kidney cancer (4) 4
kinases (4) 4
medicine, research & experimental (4) 4
open-label (4) 4
patients (4) 4
prognosis (4) 4
receptors, vascular endothelial growth factor - antagonists & inhibitors (4) 4
resistance (4) 4
specific therapeutic activity of chemical compounds ormedicinal preparations (4) 4
targeted therapy (4) 4
urology & nephrology (4) 4
vegf (4) 4
xenograft model antitumor assays (4) 4
allografts (3) 3
analysis (3) 3
anti-angiogenic therapy (3) 3
antineoplastic agents - pharmacology (3) 3
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
antitumor-activity (3) 3
cabozantinib (3) 3
carcinoma, renal cell (3) 3
carcinoma, renal cell - genetics (3) 3
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


MONTHLY NOTICES OF THE ROYAL ASTRONOMICAL SOCIETY, ISSN 0035-8711, 04/2018, Volume 475, Issue 3, pp. 3117 - 3120
In the present communication, the variation of the fractal dimension of solar radio flux is reported. Solar radio flux observations on a day to day basis at... 
Sun: corona | FLARES | CORONAL ROTATION | ASTRONOMY & ASTROPHYSICS | Sun: activity | EMISSION | Sun: radio radiation | CYCLE | Fluctuations | Correlation | Solar activity cycles | Variability | Solar maximum | Flux | Radio | Fractals | Solar minimum | Sunspot cycle | Solar activity | Sunspot numbers | Photovoltaic cells | Mathematical analysis | Randomness | Corona | Solar cycle | Low frequencies | Sunspots
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2018, Volume 36, Issue 6_suppl, pp. 58 - 58
Journal Article
Clinical cancer research : an official journal of the American Association for Cancer Research, ISSN 1078-0432, 08/2019, Volume 25, Issue 20, pp. 6098 - 6106
The use of VEGFR TKIs for the adjuvant treatment of renal cell carcinoma (RCC) remains controversial. We investigated the effects of adjuvant VEGFR TKIs on... 
Index Medicus
Journal Article
Toxicology Reports, ISSN 2214-7500, 2018, Volume 5, pp. 270 - 277
Nephrotoxicity is a major limiting factor in cisplatin treatment. In the present study hydro-ethanolic leaf extract of was investigated for its protective role... 
Rats | Oxidative stress | Emblica officinalis | Nephrotoxicity | Cisplatin
Journal Article
PLoS ONE, ISSN 1932-6203, 2011, Volume 6, Issue 4, p. e19144
Journal Article
Cancer, ISSN 0008-543X, 02/2017, Volume 123, Issue 4, pp. 576 - 582
BACKGROUND Upregulation of sphingosine‐1‐phosphate (S1P) may mediate resistance to vascular endothelial growth factor (VEGF)‐directed therapies and inhibit... 
renal cell carcinoma | sphingosine‐1‐phosphate (S1P) | sonepcizumab | resistance | sphingosine-1-phosphate (S1P) | CABOZANTINIB | EVEROLIMUS | PAZOPANIB | OPEN-LABEL | COMBINATION | THERAPY | ONCOLOGY | SUNITINIB | NIVOLUMAB | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Carcinoma, Renal Cell - genetics | Male | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Vascular Endothelial Growth Factor A - genetics | Carcinoma, Renal Cell - immunology | Lysophospholipids - immunology | Drug-Related Side Effects and Adverse Reactions - pathology | Neoplasm Metastasis | Aged, 80 and over | Female | Von Hippel-Lindau Tumor Suppressor Protein - genetics | Carcinoma, Renal Cell - drug therapy | Nuclear Proteins - genetics | Lysophospholipids - antagonists & inhibitors | Carcinoma, Renal Cell - pathology | Sphingosine - antagonists & inhibitors | Kaplan-Meier Estimate | Sphingosine - immunology | Transcription Factors - genetics | Disease-Free Survival | Sphingosine - analogs & derivatives | Antibodies, Monoclonal - administration & dosage | Aged | Biomarkers, Tumor - genetics | Care and treatment | Research | Carcinoma, Renal cell | Vascular endothelial growth factor | Sphingosine | TOR protein | Phosphates | Slopes | Therapy | Profiling | Terminology | Medical services | Metastasis | Criteria | Immunity | Sphingosine 1-phosphate | Metastases | Consortia | Antagonism | Bioindicators | Safety | Constipation | Cell survival | Health risks | Fatigue | Nausea | Rapamycin | Patients | Survival | Inhibitors | Immune checkpoint | Biomarkers | VHL protein | Neoplasia | Clear cell-type renal cell carcinoma | Cancer | Kidney transplantation
Journal Article
Cancer, ISSN 0008-543X, 10/2012, Volume 118, Issue 19, pp. 4777 - 4784
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 02/2015, Volume 21, Issue 3, pp. 561 - 568
Journal Article
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 07/2017, Volume 23, Issue 14, pp. 3557 - 3565
Purpose: Activin receptor-like kinase 1 (ALK1) is a novel target in angiogenesis. Concurrent targeting of ALK1 and VEGF signaling results in augmented... 
INTERFERON-ALPHA | HEREDITARY HEMORRHAGIC TELANGIECTASIA | EVEROLIMUS | ONCOLOGY | KINASE-1 LIGAND TRAP | SUNITINIB | RECEPTOR | OPEN-LABEL | PHASE-2 | ANTITUMOR-ACTIVITY | ALK1 | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Recombinant Fusion Proteins - adverse effects | Humans | Middle Aged | Activin Receptors, Type II - antagonists & inhibitors | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carcinoma, Renal Cell - genetics | Imidazoles - administration & dosage | Male | Indazoles - administration & dosage | Protein Kinase Inhibitors - adverse effects | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Immunoglobulin Fc Fragments - administration & dosage | Vascular Endothelial Growth Factor A - genetics | Dose-Response Relationship, Drug | Angiogenesis Inhibitors - administration & dosage | Activin Receptors, Type II - administration & dosage | Female | Carcinoma, Renal Cell - drug therapy | Angiogenesis Inhibitors - adverse effects | Immunoglobulin Fc Fragments - adverse effects | Recombinant Fusion Proteins - administration & dosage | Carcinoma, Renal Cell - pathology | Imidazoles - adverse effects | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Activin Receptors, Type II - genetics | Aged | Indazoles - adverse effects | Neoplasm Staging | Activin Receptors, Type II - adverse effects | Cell culture | Toxicity | Syngeneic grafts | Medical services | Kinases | Anticancer properties | Proteins | Angiogenesis | Allografts | Quality | Safety engineering | Xenografts | Bone morphogenetic proteins | Safety | Fusion protein | Vascular endothelial growth factor | Protein-tyrosine kinase | Tyrosine | Edema | Pharmacodynamics | Effusion | Diarrhea | Fatigue | Pharmacology | Patients | Vascular endothelial growth factor receptors | Intolerance | Signaling | Experimental design | Antitumor activity | Pharmacokinetics | Activin | Clear cell-type renal cell carcinoma | Cancer | Index Medicus
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 04/2015, Volume 21, Issue 8, pp. 1925 - 1934
Purpose: VEGFR2 tyrosine kinase inhibition (TKI) is a valuable treatment approach for patients with metastatic renal cell carcinoma (RCC). However, resistance... 
ANTIANGIOGENIC THERAPY | INTERFERON-ALPHA | SPHINGOSINE KINASE 1 | ONCOLOGY | POOR SURVIVAL | GROWTH | SPHINGOSINE-1-PHOSPHATE | SORAFENIB | EXPRESSION | CELL CARCINOMA | 1-PHOSPHATE | Lysophospholipids - metabolism | Up-Regulation | Kidney Neoplasms - genetics | Humans | Gene Expression Regulation, Neoplastic | Transcriptome | Drug Resistance, Neoplasm | Gene Expression Profiling | Kidney Neoplasms - metabolism | Gene Regulatory Networks | Neoplasm Metastasis | Receptors, Vascular Endothelial Growth Factor - metabolism | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Female | Antineoplastic Agents - pharmacology | Sphingosine - metabolism | Disease Models, Animal | Lysophospholipids - antagonists & inhibitors | Sphingosine - antagonists & inhibitors | Antibodies, Monoclonal - pharmacology | Phosphotransferases (Alcohol Group Acceptor) - genetics | Phosphotransferases (Alcohol Group Acceptor) - metabolism | Xenograft Model Antitumor Assays | Sphingosine - analogs & derivatives | Animals | Tumor Burden - drug effects | Neovascularization, Pathologic - drug therapy | Cell Line, Tumor | Kidney Neoplasms - pathology | Mice | Protein Kinase Inhibitors - pharmacology | Kidney Neoplasms - drug therapy | Cluster Analysis | VEGFR | sphingosine -1- phosphate | Renal cell carcinoma | sphingosine kinase 1
Journal Article
Journal Article